vs
CareTrust REIT, Inc.（CTRE）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是CareTrust REIT, Inc.的1.5倍（$207.3M vs $134.9M），CareTrust REIT, Inc.净利率更高（82.5% vs -62.0%，领先144.5%），CareTrust REIT, Inc.同比增速更快（55.1% vs 25.9%），过去两年CareTrust REIT, Inc.的营收复合增速更高（46.2% vs 38.0%）
本公司是一家英国房地产投资企业，专注于医疗类不动产投资，持有规模庞大的养老护理院资产组合。公司采用房地产投资信托（REIT）架构，在伦敦证券交易所上市，是富时250指数成分股。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CTRE vs RARE — 直观对比
营收规模更大
RARE
是对方的1.5倍
$134.9M
营收增速更快
CTRE
高出29.2%
25.9%
净利率更高
CTRE
高出144.5%
-62.0%
两年增速更快
CTRE
近两年复合增速
38.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $134.9M | $207.3M |
| 净利润 | $111.3M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 82.5% | -62.0% |
| 营收同比 | 55.1% | 25.9% |
| 净利润同比 | 113.5% | 3.5% |
| 每股收益（稀释后） | $0.52 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTRERARE
| Q4 25 | $134.9M | $207.3M | ||
| Q3 25 | $132.4M | $159.9M | ||
| Q2 25 | $112.5M | $166.5M | ||
| Q1 25 | $96.6M | $139.3M | ||
| Q4 24 | $86.9M | $164.6M | ||
| Q3 24 | $77.4M | $139.5M | ||
| Q2 24 | $68.9M | $147.0M | ||
| Q1 24 | $63.1M | $108.8M |
净利润CTRERARE
| Q4 25 | $111.3M | $-128.6M | ||
| Q3 25 | $74.9M | $-180.4M | ||
| Q2 25 | $68.5M | $-115.0M | ||
| Q1 25 | $65.8M | $-151.1M | ||
| Q4 24 | $52.1M | $-133.2M | ||
| Q3 24 | $33.4M | $-133.5M | ||
| Q2 24 | $10.8M | $-131.6M | ||
| Q1 24 | $28.7M | $-170.7M |
营业利润率CTRERARE
| Q4 25 | — | -54.7% | ||
| Q3 25 | 58.1% | -106.9% | ||
| Q2 25 | 61.3% | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | 43.0% | -94.6% | ||
| Q2 24 | 15.1% | -79.1% | ||
| Q1 24 | — | -151.9% |
净利率CTRERARE
| Q4 25 | 82.5% | -62.0% | ||
| Q3 25 | 56.6% | -112.8% | ||
| Q2 25 | 60.9% | -69.0% | ||
| Q1 25 | 68.1% | -108.5% | ||
| Q4 24 | 60.0% | -80.9% | ||
| Q3 24 | 43.2% | -95.7% | ||
| Q2 24 | 15.6% | -89.5% | ||
| Q1 24 | 45.6% | -156.8% |
每股收益（稀释后）CTRERARE
| Q4 25 | $0.52 | $-1.28 | ||
| Q3 25 | $0.35 | $-1.81 | ||
| Q2 25 | $0.35 | $-1.17 | ||
| Q1 25 | $0.35 | $-1.57 | ||
| Q4 24 | $0.30 | $-1.34 | ||
| Q3 24 | $0.21 | $-1.40 | ||
| Q2 24 | $0.07 | $-1.52 | ||
| Q1 24 | $0.22 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.0M | $421.0M |
| 总债务越低越好 | $894.2M | — |
| 股东权益账面价值 | $4.0B | $-80.0M |
| 总资产 | $5.1B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.22× | — |
8季度趋势，按日历期对齐
现金及短期投资CTRERARE
| Q4 25 | $198.0M | $421.0M | ||
| Q3 25 | $712.5M | $202.5M | ||
| Q2 25 | $306.1M | $176.3M | ||
| Q1 25 | $26.5M | $127.1M | ||
| Q4 24 | $213.8M | $174.0M | ||
| Q3 24 | $377.1M | $150.6M | ||
| Q2 24 | $495.1M | $480.7M | ||
| Q1 24 | $451.2M | $112.3M |
总债务CTRERARE
| Q4 25 | $894.2M | — | ||
| Q3 25 | $893.8M | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $822.1M | — | ||
| Q4 24 | $396.9M | — | ||
| Q3 24 | $396.7M | — | ||
| Q2 24 | $671.1M | — | ||
| Q1 24 | $595.9M | — |
股东权益CTRERARE
| Q4 25 | $4.0B | $-80.0M | ||
| Q3 25 | $4.0B | $9.2M | ||
| Q2 25 | $3.3B | $151.3M | ||
| Q1 25 | $2.9B | $144.2M | ||
| Q4 24 | $2.9B | $255.0M | ||
| Q3 24 | $2.4B | $346.8M | ||
| Q2 24 | $1.9B | $432.4M | ||
| Q1 24 | $1.7B | $140.3M |
总资产CTRERARE
| Q4 25 | $5.1B | $1.5B | ||
| Q3 25 | $5.1B | $1.2B | ||
| Q2 25 | $4.7B | $1.3B | ||
| Q1 25 | $3.9B | $1.3B | ||
| Q4 24 | $3.4B | $1.5B | ||
| Q3 24 | $2.9B | $1.5B | ||
| Q2 24 | $2.7B | $1.6B | ||
| Q1 24 | $2.3B | $1.3B |
负债/权益比CTRERARE
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.28× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $394.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 3.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流CTRERARE
| Q4 25 | $394.0M | $-99.8M | ||
| Q3 25 | $100.9M | $-91.4M | ||
| Q2 25 | $100.8M | $-108.3M | ||
| Q1 25 | $71.4M | $-166.5M | ||
| Q4 24 | $244.3M | $-79.3M | ||
| Q3 24 | $67.2M | $-67.0M | ||
| Q2 24 | $53.0M | $-77.0M | ||
| Q1 24 | $48.8M | $-190.7M |
自由现金流CTRERARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率CTRERARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度CTRERARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
现金转化率CTRERARE
| Q4 25 | 3.54× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 4.68× | — | ||
| Q3 24 | 2.01× | — | ||
| Q2 24 | 4.92× | — | ||
| Q1 24 | 1.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTRE
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
